
ClearPoint Neuro CLPT
$ 9.78
-12.37%
Annual report 2025
added 03-17-2026
ClearPoint Neuro Accounts Receivables 2011-2026 | CLPT
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables ClearPoint Neuro
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.55 M | 4.71 M | 3.21 M | 2.66 M | 2.34 M | 1.88 M | 1.09 M | 1.23 M | 949 K | 866 K | 1.22 M | 469 K | 770 K | 445 K | 402 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.55 M | 402 K | 1.92 M |
Quarterly Accounts Receivables ClearPoint Neuro
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 M | 4.26 M | 3.65 M | 4.71 M | 3.88 M | 3.48 M | 2.51 M | 3.21 M | 2.42 M | 2.8 M | 2.68 M | 2.66 M | 3.41 M | 3.35 M | 2.24 M | 2.34 M | 2.56 M | 2.41 M | 2 M | 1.88 M | 1.88 M | 1.88 M | 1.88 M | 1.09 M | 1.09 M | 1.09 M | 1.09 M | 8 K | 1.23 M | 1.23 M | 1.23 M | 949 K | 949 K | 949 K | 949 K | 866 K | 866 K | 866 K | 866 K | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 469 K | 469 K | 469 K | 469 K | 770 K | 770 K | 770 K | 770 K | 445 K | 445 K | 445 K | 445 K | 402 K | 402 K | 402 K | 402 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.71 M | 8 K | 1.6 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
128 K | $ 2.2 | -0.45 % | $ 3.43 M | ||
|
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | ||
|
AdaptHealth Corp.
AHCO
|
371 M | $ 10.54 | 0.86 % | $ 1.42 B | ||
|
Alphatec Holdings
ATEC
|
97.3 M | $ 12.8 | -1.92 % | $ 1.92 B | ||
|
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | ||
|
Cognyte Software Ltd.
CGNT
|
175 M | $ 8.37 | 0.12 % | $ 601 M | ||
|
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | ||
|
Butterfly Network
BFLY
|
20.8 M | $ 4.04 | -5.28 % | $ 855 M | ||
|
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | ||
|
Cytosorbents Corporation
CTSO
|
7.32 M | $ 0.66 | -3.66 % | $ 35.9 M | ||
|
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | ||
|
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
18.6 M | $ 3.86 | -4.93 % | $ 144 M | ||
|
CONMED Corporation
CNMD
|
248 M | $ 36.87 | -0.83 % | $ 1.14 B | ||
|
Establishment Labs Holdings
ESTA
|
77.5 M | $ 64.93 | -0.12 % | $ 1.92 B | ||
|
Cutera
CUTR
|
43.1 M | - | -10.19 % | $ 1.99 M | ||
|
InMode Ltd.
INMD
|
10.5 M | $ 13.45 | -1.47 % | $ 869 M | ||
|
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | ||
|
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | ||
|
Abbott Laboratories
ABT
|
7.93 B | $ 107.89 | -2.58 % | $ 188 B | ||
|
IRIDEX Corporation
IRIX
|
6.73 M | $ 1.33 | - | $ 21.5 M | ||
|
Delcath Systems
DCTH
|
11.7 M | $ 9.45 | -2.98 % | $ 339 M | ||
|
Bio-Rad Laboratories
BIO
|
452 M | $ 270.01 | 0.23 % | $ 7.62 B | ||
|
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 16.7 | -2.96 % | $ 392 M | ||
|
Helius Medical Technologies
HSDT
|
117 K | $ 2.1 | -3.46 % | $ 1.28 M | ||
|
AxoGen
AXGN
|
26.2 M | $ 31.03 | -5.25 % | $ 1.43 B | ||
|
Align Technology
ALGN
|
996 M | $ 173.18 | -1.67 % | $ 13 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
272 M | $ 8.9 | -2.25 % | $ 685 M | ||
|
Bruker Corporation
BRKR
|
566 M | $ 34.44 | 2.07 % | $ 5.13 K | ||
|
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
16.8 M | $ 3.7 | -1.07 % | $ 152 M | ||
|
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | ||
|
Accuray Incorporated
ARAY
|
83.2 M | $ 0.42 | 7.69 % | $ 43.2 M | ||
|
IRadimed Corporation
IRMD
|
13.7 M | $ 101.65 | -1.12 % | $ 1.29 B |